COIOSDeep risk insights through multi-disciplinary research across the globe
a tall building with lots of windows next to a street
Item refines Peer-reviewed Added

Biosimilar launch after approval was faster in Japan than in the USA and the EU

Japan approved biosimilars later, yet launched them a median 6 months after approval, against 15 (USA) and 17 (EU).

The study compared biosimilar approval and launch dates in Japan, the USA and the EU. It also measured patient access time, the interval from approval to first commercial launch. Data came from public PMDA, FDA and EMA records, supplemented by company press releases. Median patient access time was 6 months in Japan, 15 months in the USA and 17 months in the EU. Japan still approved biosimilars later, yet its first launches were often as early as or earlier than elsewhere. Launch marks only the earliest point of access, not later uptake in clinical practice.

Why it is interesting: Approval dates alone can misstate when patients can actually obtain a biosimilar. The authors argue that assessing access also requires looking at post-approval steps such as market entry, pricing and reimbursement.

Source
Naunyn-Schmiedeberg's Archives of Pharmacology, 21 November 2026
Paper
From regulatory approval to patient access: A comparative analysis of biosimilar market entry timelines in Japan, the USA, and the EU
Authors
Kawasaki M, Saino Y, Nishizawa A, Hariu A, Kuribayashi R
DOI
10.1007/s00210-026-06048-4
Type
Peer-reviewed article
Design
Descriptive comparative analysis of regulatory and launch dates from PMDA, FDA and EMA public records plus company press releases; median approval-to-launch interval compared across three jurisdictions (n of products not stated)
Verdict
Refines prior evidence
Driver
Innovation in treatment

Other drivers in Tomorrow's world